2022
Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury
Sprangers B, Leaf DE, Porta C, Soler MJ, Perazella MA. Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. Nature Reviews Nephrology 2022, 18: 794-805. PMID: 36168055, DOI: 10.1038/s41581-022-00630-8.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsAcute kidney injuryKidney injuryKidney biopsyAcute tubulo-interstitial nephritisImmune-related adverse eventsConcomitant anticancer therapyTubulo-interstitial nephritisEffector T cellsEvaluation of patientsLoss of toleranceCheckpoint inhibitorsPartial remissionPermanent discontinuationAdverse eventsMost patientsAppropriate treatmentEarly initiationT cellsClinical practiceFavorable responsePatientsAccurate diagnosisCancer treatmentAnticancer therapy
2015
Thrombotic Microangiopathy, Cancer, and Cancer Drugs
Izzedine H, Perazella MA. Thrombotic Microangiopathy, Cancer, and Cancer Drugs. American Journal Of Kidney Diseases 2015, 66: 857-868. PMID: 25943718, DOI: 10.1053/j.ajkd.2015.02.340.Peer-Reviewed Original ResearchConceptsDrug-induced thrombotic microangiopathyThrombotic microangiopathyAnti-vascular endothelial growth factor agentsEndothelial growth factor agentsLong-term kidney injuryManagement of TMACell damageGrowth factor agentsAnti-VEGF agentsEndothelial cell damageType I agentsChemotherapy regimensDrug interruptionFactor agentsKidney injuryImmunologic basisClinical courseFunctional recoveryImmunosuppressive agentsKidney functionCertain malignanciesI agentsPhysician guidanceAnticancer therapySuccessful diagnosis